University of Central Florida

STARS
Honors Undergraduate Theses

UCF Theses and Dissertations

2021

Pineal Gland Abnormalities and the Relationship of Melatonin to
the Development and Symptom Severity of Schizophrenia: An
Integrative Review of the Literature
Kathryn Margretta
University of Central Florida

Part of the Psychiatric and Mental Health Nursing Commons

Find similar works at: https://stars.library.ucf.edu/honorstheses
University of Central Florida Libraries http://library.ucf.edu
This Open Access is brought to you for free and open access by the UCF Theses and Dissertations at STARS. It has
been accepted for inclusion in Honors Undergraduate Theses by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

Recommended Citation
Margretta, Kathryn, "Pineal Gland Abnormalities and the Relationship of Melatonin to the Development
and Symptom Severity of Schizophrenia: An Integrative Review of the Literature" (2021). Honors
Undergraduate Theses. 913.
https://stars.library.ucf.edu/honorstheses/913

PINEAL GLAND ABNORMALITIES AND THE RELATIONSHIP OF MELATONIN TO
THE DEVELOPMENT AND SYMPTOM SEVERITY OF SCHIZOPHRENIA: AN
INTEGRATIVE REVIEW OF THE LITERATURE

By

KATHRYN MARGRETTA

Spring Term, 2021

Thesis Chair: Dr. Angeline Bushy

Abstract

The purpose of this thesis is to critique the literature focusing on the role of pineal gland
volume and function and the development of schizophrenia by asking the question, “What is the
relationship between pineal gland physiologic function and development and symptom severity
of schizophrenia? It is crucial that health care providers continue advocate for better
understanding of schizophrenia in order to develop a more appropriate treatment and relive the
suffering of those with schizophrenia. A review of published literature focusing on the pineal
glands association with schizophrenia was performed using several databases including:
ScienceDirect, PubMED, Google Scholar, Cumulated Index to Nursing and Allied Health
Literature (CINAHL), and Elton B. Stephens Co. (EBESCO). Key search terms included: Pineal
gland, melatonin and schizophrenia, pineal gland and schizophrenia, sleep and schizophrenia,
melatonin and treatment for schizophrenia, alternative treatments for schizophrenia, and pineal
volume and schizophrenia. Based on current researching findings, it is my prediction that the
chief consensus among the literature will be that physiologic abnormalities often coincided with
schizophrenia, but do not indicate the severity of the disease or seem to have a strong correlation
to the cause of the disease. It is also my prediction that alternative therapies will be beneficial in
reducing symptoms severity, and adverse effects cause by psychiatric medications.
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Introduction
Diagnosed commonly in late adolescence or early adulthood, schizophrenia affects
around one percent of the population worldwide. By this estimate, schizophrenia and
schizophrenia related disorders affect an estimated 3 million people in the United States
(Videbeck, 2019). Rather than a singular disease, schizophrenia is considered as a syndrome or
disease process with variability in symptoms, presentations, and severity. Symptoms of
schizophrenia are classified into two general categories: positive or negative. In either category,
symptoms can impose life changing challenges, making it difficult for the individual to have a
fully functioning lifestyle. Fortunately, pharmacology interventions and community-based care
have made it possible for many individuals with schizophrenia to successfully integrate and lead
healthy lives. Still, the exact pathophysiology for the disease is unknown.
A recent theory describes irregularities in the pineal gland as a potential contributing
factor for this disorder. The pineal gland, sometimes called the “third eye” or the “seat of the
soul”, located at the frontal center of the brain, between the crevice where the two halves of the
thalamus join, the pineal gland is responsible for sensing light (or, lack thereof) and secreting
melatonin in response (Aulinas, 2019). As a result, the pineal gland regulates sleep-wake cycles,
circadian rhythm, cell protection, and neuroprotection (Aulinas, 2019). Recently, researchers
noted physiological abnormalities in the pineal gland among individuals with schizophrenia. This
finding suggests that the pineal gland volume and function may have a role in development of
the disease and associated symptoms.
It is crucial that health care providers continue advocate for better understanding of
schizophrenia, in order to develop a more appropriate treatment. Current first line treatments for
1

individuals with schizophrenia are primarily pharmacologic in nature. The development of
Chlorpromazine (Thorazine) in 1952, proved to be revolutionary for treatment of schizophrenia
and other types of mental illness. Prior to the development of this medication, individuals with
schizophrenia most often were institutionalized and sometimes treated through electroshock
therapy (Patel, 2014). Since then, other pharmacologic agents have been developed, and these
continue to be a paramount source of treatment for individuals with schizophrenia.
Without a clear understanding of the cause of the disease, health care providers are only
able to treat the symptoms of schizophrenia. However, psychotropic pharmacologic agents are
not without side effects: weight gain, sedation, seizures, and movement disorder such as tardive
dyskinesia are unfortunately common (Kane, 2010). Alternative therapies, particularly those
involving the pineal gland and melatonin, should be further explored. More research is needed
into the pineal gland and its potential to demystify the disease process present in schizophrenia.
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Problem statement

What is the relationship between pineal gland physiologic function and development of
schizophrenia?

3

Purpose

The purpose of this thesis is to critique the literature focusing on the role of melatonin
and pineal gland abnormalities in the development and symptoms severity of schizophrenia.

4

Literature Review
As previously noted, schizophrenia is not a specific disease. Rather, this diagnosis
includes a range of symptoms and behaviors; often classified as “positive” or “negative”.
Positive symptoms refer to “extra” behaviors or experiences that manifest in the form of
delusions, flight of ideas, ambivalence, bizarre behavior, loose associations, echopraxia,
hallucinations, preservation, and ideas of reference. On the other hand, negative symptoms refer
to impaired emotion or affect. Examples of negative symptoms include alogia, anhedonia,
apathy, asociality, blunted affect, catatonia, flat affect, avolition, and inattention (Sarkar, 2015).
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
criteria for schizophrenia requires the presence of two or more of the following symptoms,
present for at least on month:
•

Delusions

•

Hallucinations

•

Disorganized speech (e.g., frequent derailment or incoherence)

•

Grossly disorganized or catatonic behavior

•

Negative symptoms (i.e., diminished emotional or avolition).

Of these 5 symptoms, one of the two must be delusions, hallucinations or disorganized
speech in order to warrant a schizophrenia diagnosis (Substance Abuse and Mental Health
Services Administration, 2016). Nurses should be aware that individuals with schizophrenia are
at risk for disturbed thought process and self-care deficit, and plan care accordingly. To
understand the potential role of the pineal gland and its role in schizophrenia, theories on
5

schizophrenia, pineal gland function, current treatments, and pineal abnormalities must first be
explored.
Theories associated with development of Schizophrenia

In the past, the etiology of schizophrenia was hypothesized to have social and
interpersonal origins, however, the more prevalent current school of thought focuses largely on
the biologic factors at play. Evidence supporting the argument for biologic causes has proven to
be more frequent and widely accepted then its sociologic counterpart. Presently, genetics,
viruses, and neuroanatomy or neurochemicals disturbances are hypothesized to be the three
predominant causes of schizophrenia (Videbeck, 2019). Current genetic theories suggest that
schizophrenia is a polygenetic trait, meaning that multiple genes attribute to the development of
the disorder. This theory is supported by studies conducted in families, particularly with identical
twins. When one identical twin has schizophrenia, the other twin has a 50% chance of
developing the disorder. On the other hand, fraternal twins only present a 15% risk of developing
this condition (Videbeck, 2019). If the etiology of schizophrenia related to only one gene, both
identical twins would develop schizophrenia. To date, genetic research focusing on
schizophrenia has not identified a particular gene or genes that are responsible for the disorder.
Another theory focusing on the biologic etiology of schizophrenia relates to
immunovirology- that is, the body’s response to a virus. The immunovirology theory attributes
the development of schizophrenia to childhood or prenatal exposure to certain viruses. This
theory is supported by the rise in schizophrenia cases a generation after waves of flu affected
England in the mid-1900s (Brown & Derkits, 2010). Additionally, the role of cytokines in
6

infection and mental health have been brought to question. The key role of cytokines is to
mediate inflammatory and immune responses. However, cytokines have a lesser known function,
that is, behavior and neurochemical modulation. The theory of immunovirology hypothesizes
that exposure to viruses and the reaction of cytokines results in changes to behavior and
neurochemistry
Neuroanatomy and neurochemical disturbances also pose a potential cause of
schizophrenia. As if a culmination of multiple theories, the neuroanatomy theory observes that
individuals with schizophrenia have differences in brain structure compared with those without
schizophrenia. These anatomic differences include less cerebral spinal fluid and brain tissues in
affected individuals, as well as larger ventricles and diminished glucose and oxygen metabolism
(Skudlarski, 2010). Neurochemical differences include excess production of dopamine and
serotonin. An excess of dopamine is a commonly cited immediate cause for the symptoms of
schizophrenia. The influence of melatonin, regulated by the pineal gland, will be discussed
further in this thesis. Research on the pineal gland warrants further discussion on a potential
biologic factor associated with schizophrenia, particularly the theory of neuroanatomy.
A rising star: The pineal gland and melatonin
The understand the role of the pineal gland in schizophrenia, the role of this gland in a
neurotypical brain must be examined. The pineal gland, located between the two hemispheres of
the brain, is best known for its role in melatonin secretion, and regulation of the circadian
rhythm. Melatonin, a derivative of serotonin, is secreted relative to the amount of light detected
by the retinas of the eye. In a well-functioning pineal gland, exposure to light will decrease the
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secretion of melatonin by the pineal gland, resulting in wakefulness (Aulinas, 2019). Conversely,
a lack of light, such as during evening time, will promote secretion of melatonin, resulting in
drowsiness. While the role of melatonin and the sleep-wake cycle should not be understated, the
melatonin and the pineal gland affect a variety other system as well. Melatonin is related to
memory, growth hormone secretion, ovarian physiology, and osteoblast differentiation (Aulinas,
2019). The unique properties of melatonin include antinociception, antidepression, anxiolytic,
locomotor activity-regulating, neuroprotective, anti-inflammatory, pain-modulating, along with
blood pressure-reducing, retinal, vascular, anti-tumor, and antioxidant effects (Emet, 2016).
The systemic effect of melatonin can be partially attributed to the widespread prevalence
of melatonin receptors in the body. Melatonin receptors can be found in the brain, retina,
cardiovascular system, cardiac ventricular wall, aorta, coronary and cerebral arteries, liver and
gallbladder, duodenal enterocytes, colon, cecum and appendix vermiformis, skin, parotid gland,
exocrine pancreas, kidney, cells of immune system, platelets, brown and white adipocytes,
epithelial cells of prostate and breast, ovary/granulosa cells, myometrium, placenta and fetal
kidney (Emet, 2016). One reason melatonin is more widely researched is associated with its
unique property to pass through the blood brain barrier and accumulate in the central nervous
system at a rate higher than most neurochemicals (Andrabi, 2019). As a result, melatonin can
produce strong neurochemical affects. Perhaps most key to schizophrenia is melatonin’s
dopamine inhibiting properties. Previous studies have explored the role of melatonin and
dopamine inhibition in the context of Alzheimer’s, Parkinson’s, and strokes, and the findings are
promising for melatonin’s role in schizophrenia. Consequently, the role of melatonin and the
pineal gland on dopaminergic system is of key importance.
8

Current treatment
As previously discussed, modern treatment of schizophrenia relies heavily on
pharmacologic interventions. Specifically, symptom management of schizophrenia is achieved
through first- and second-generation antipsychotic medications. First generation antipsychotic
mediations work well to reduce the positive signs of schizophrenia such as hallucinations,
disturbed thinking, and delusions. The first-generation medication are dopamine agonists, and
work by inhibiting blocking the D2, D3, and D4 receptors of the neurotransmitter dopamine
(Kane, 2010). Second generation antipsychotics work by blocking the receptors of both
dopamine and serotonin. The effect on serotonin enables second generation antipsychotic to
manage both the positive and negative signs of schizophrenia. Some antipsychotics can be given
in injections to combat the skipping or misuse of medication by individuals with schizophrenia.
The paramount dilemma with administering antipsychotic medication is the side effects. For
antipsychotics, extrapyramidal side effects are of particular concern. Extrapyramidal (EPS) side
effects refers to a collection of neurologic symptoms that occur due to the blockage of the D2
receptor in the brain stem (Weng, 2019).
Among others, EPS can include, among others, acute dystonia, tardive dyskinesia,
neuroleptic malignant syndrome, psuedoparkinsonisms, and akathisia. Additional side effects
include metabolic syndrome, decreased libido, and an increased risk for breast cancer (Weng,
2019). Another downside to associated with psychopharmacology side effects serve as barriers,
to individuals with schizophrenia adhering to their recommended treatment regimen. Adherence
barriers may be associated with socioeconomic factors, such as an inability to pay for the
medicine, or lack of transportation to obtain medicine. Medication nonadherence often is
9

attributed to unpleasant side effects, difficulty adhering to a schedule, belief that the individual
“doesn’t need” the medication or feels worse while being on the medication. While psychotropic
pharmacology has been incredibly beneficial to the management of schizophrenia, understanding
the role of the pineal gland in schizophrenia might enable providers to treat the disorder more
effectively with fewer negative side effects.
Changes to the pineal gland
Changes to the pineal gland lead to subsequent alteration to the systems that are
influenced by the gland. Possible alteration to the pineal gland my occurs due to a variety of
factors such as smoking, inadequate in utero nutrition, or obesity along with environmental
exposures such as fluorides, tobacco, and some food additives (Takahashi, 2019).
Several studies investigated anatomic differences in the pineal glands of individuals with
schizophrenia. The most frequent abnormality observed was a decrease pineal volume in those
with schizophrenia (Takahashi, 2019). However, results have not been consistent (Aulinas,
2019). For example, early studies of pineal volume in individuals with schizophrenia found no
abnormalities, but more recent literature attributes decreased pineal volume to early
neurobiological alterations. The current literature, however, suggests that pineal gland volume
does not change over time in affected individuals (Takahashi, 2019). Hence, individuals with
chronic schizophrenia maintain pineal volume despite living with the disorder for a longer time.
Similarly, pineal volume did not change with dose or duration of antipsychotic medication
(Takahashi, 2019). These findings indicate decreased pineal volume could be a risk factor for
development of schizophrenia, rather than a cause of the disease. However, it should also be
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noted that behaviors that lead to pineal abnormalities parallel risk factors for development of
schizophrenia (ex. Smoking, poor nutrition, obesity).
Lack of correlation between pineal volume and severity of symptoms further supports the
theory that the pineal gland has not yet been found to be a convincing risk of developing
schizophrenia. Perhaps more promising is the role of melatonin in affected individuals. In a study
by Morera-Fumero, decreased serum melatonin levels were found to be correlated with
conceptual disorganization (Morera-Fumero, 2011). Reports of diminished melatonin levels in
affected individuals is supported by an identical twin study. Afonso found that in the affected
twin, nighttime melatonin secretion was significantly lower than his healthy counterpart. As a
result, the affected twin experienced prolonged periods of restlessness and impaired quality of
sleep (Afonso, 2010). Research into melatonin as treatment for schizophrenia is promising, but
strong evidence is lacking at this time.
Alternative treatments and links to melatonin
Current nonpharmacological alternative treatments center primarily around melatonin
production and dietary changes. The treatment most pertinent to pineal gland involvement is
melatonin. In a study conducted on rats, melatonin was able to reduce the histological changes
caused by injection of MK-801 (Andrabi, 2019). MK-801, or Dizocilpine more specifically, is a
NMDA receptor antagonists which among other things, creates schizophrenia-like symptoms in
lab rats. The use of melatonin in diminishing these symptoms indicates that melatonin may be
useful in managing schizophrenia symptoms in affected humans. Aside from symptom treatment,
melatonin has been found to decrease the side effect of weight gain associated with the
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antipsychotic drug olanzapine. In a 2014 study by Modabbernia (N= 48), an 8 week treatment of
melatonin correlated with a 3.2 kg difference in weight gain, decreases waist circumference, and
triglyceride concentration (Modabbernia, 2014).
Other alternative theories for symptom management focus on dietary changes and
incorporating nutritional supplements. Of particular interest is the ketogenic diet and
incorporating vitamin d and folic acid supplements. Dietary modifications are of interest related
to the melatonin level in the body. Production of melatonin relies on availability of its precursor,
tryptophan. If amino acids are restricted in the diet, it may lead to a decrease in tryptophan and a
consequential decrease in melatonin (Peuhkuri, 2012). Additionally, low levels of zinc, folate,
and magnesium have been linked to lower levels of melatonin (Peuhkuri, 2012). Current research
continues to find evidence that melatonin has promise for aiding in management of
schizophrenia. Therefore, it is beneficial to understand dietary changes effect on melatonin, and
how melatonin supplements may be used alongside pharmacological and life style interventions.
Conclusion
Schizophrenia is a complicated and poorly understood psychiatric disorder. Recent
pharmacological advancements have made it possible for affected individuals to manage
symptoms. However, there are significant side effects associated with current antipsychotics.
Some correlation has been found between a decreased pineal volume, and risk for development
of schizophrenia. The use of melatonin has been supported to be effective for decreasing both
symptoms of schizophrenia and decreasing side effects associated with antipsychotic
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medications. Further research into the pineal gland and its effect on neurobiology yields promise
for deepening understanding of schizophrenia.
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Methodology
A review of published literature focusing on the pineal glands association with
schizophrenia was performed using several databases including: ScienceDirect, PubMED,
Google Scholar, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Elton
B. Stephens Co. (EBESCO). Key search terms included: Pineal gland, melatonin and
schizophrenia, pineal gland and schizophrenia, sleep and schizophrenia, melatonin and treatment
for schizophrenia, alternative treatments for schizophrenia, and pineal volume and schizophrenia.
Inclusion criteria will include research published from 1998-2020. Exclusion criteria will include
research published not in the English language, research outside of the specified published date,
or research not relevant to the topic. (See Appendix A Figure 1: Methodology Consort Chart)
An evidence table was developed to summarize the articles critiqued by the researcher
and included in the appendices. Each research article was analyzed, critiqued, synthesized, and
extracted by the researcher. Consistent and inconsistent findings along with gaps in the literature
will be discussed.
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Discussion

Throughout the literature, there have been various discussions about the pineal gland,
melatonin, and schizophrenia. The results indicate that while pineal gland abnormalities are often
present in schizophrenia, there is not yet strong evidence to suggest that these abnormalities are
causative factors in the development of schizophrenia. The literature indicates that severity in
pineal abnormalities are not linked to severity in clinical presentation of the disorder. Discussion
of melatonin in relation to schizophrenia consistently found lower serum melatonin levels in
affected individuals. Individuals with schizophrenia present largely with disrupted circadian
rhythms, linked possibly to decreased serum melatonin levels, however the literature is not
conclusive in terms of exact cause for these disruptions. Melatonin supplements have been
shown to decrease the severity of some clinical presentations of schizophrenia, however,
research on the subject is still limited.
Inconsistent findings include discussion of the severity of symptom reduction in
individuals with schizophrenia given melatonin, and which symptoms showed improvements.
Melatonin’s link to increased sleep efficiency cannot be overlooked. Inconsistent findings could
be related to the remedying of sleep deprivation and insomnia in affected individuals, and the
various responses to these strenuous circumstances.
More research is needed to isolate the efficacy of melatonin on specific populations in
varying environments. Gaps in the literature include the relationship between serotonin and
melatonin, the effectiveness of melatonin in outpatient vs inpatient settings, the effectiveness of
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melatonin on various skin pigments, ages, and sexes, and the relationship between physical
pineal abnormalities and their relation to melatonin production.

16

Implications for nursing
The next section highlights implications for nursing policy, education, practice, and
research. Limitations of this review are highlighted.
Policy
Policies such as 3rd party payers providing expanded coverage for medications and
services provided by advanced practice nurses focusing on individuals diagnosed with
schizophrenia has made improvements to the quality of life of the affected population and their
caregivers, however, there are still reimbursement policies to be made. To start, community
based mental health services require increased funding. Funding for mental health resources is
sources primarily from the federal or state level and in some cases local tax initiatives. While
large financial investments are dedicated to mental health services, the percentage of the
population who are utilizing such services does not correlate. For example, Florida spends over
700 million dollars on State Mental Health Agency Expenditures annually, but less than 2% of
the Florida population utilizes these services (National Rehabs Directory, 2019). This ratio
highlights another necessary policy change: programs that promote accessibility of services. One
of the many systemic factors that prevent individuals with schizophrenia from seeking or
following up with care is the lack of accessibility associated with transportation, location, or
financial constraints (Wood, 2014). Many individuals with schizophrenia also have dual
diagnoses such as substance abuse, homelessness, or veteran status, which pose additional
barriers to care. Policy changes to improve accessibility of care may include improving public
transportation through adequate funding, as well as greater involvement of state sanctioned
17

guardians in follow up care for those with a diagnosis of schizophrenia. There is much to be done
in the way of policy changes to support individuals with schizophrenia, but fiscal support for
community-based programs and more user-friendly transportation would help bridge some of the
gaps where inaccessibility to care thrives.
Education
The educational workload surround schizophrenia lies mostly in public
destigmatization of the disorder. Although greater awareness for the disorder has led to improved
public perceptions, stigma remains as one of the greatest challenges to those with a
schizophrenia diagnosis. In a 2008 study that surveyed 1070 individuals from the English public
about their attitudes towards mental illnesses, in the study, 63% of participants believed those
with schizophrenia to be a danger to others, 54% reported believing that those affected “feel
different from us”, and 50% labeled those with schizophrenia as hard to talk to (Wood, 2014).
Public programs aimed at reducing stigma have been somewhat successful in the past. In a fiveyear campaign (1998) entitled ‘Changing Minds : Every Family in the Land’ had some success
in altering public attitudes regarding individuals with schizophrenia (Crisp, 2000). Objectives
for public education should center around highlighting statistics that support perception of
individuals with schizophrenia as more of a threat to themselves than others, health disparities
faced by those with a schizophrenia diagnosis, information on local resources, and teachings
regarding how to handle an individual experiencing psychosis in a safe and helpful manner.
Similar objectives would be beneficial if integrated into psych or advanced practice nurse
practitioner curricula. Table 2: Teaching Proposal illustrates an example of a teaching proposal
that would be appropriate for a community outreach education session.
18

Nursing practice
Implications for nursing practice include increased use of alternative therapies for
symptom management such as melatonin supplements and sunlight exposure. Melatonin
supplements have been shown to reduce symptom severity in individuals with schizophrenia. A
2007 study found that 3mg of melatonin administered to schizophrenic patients suffering from
insomnia improved the quality and depth of nighttime sleep, reduced the number of nighttime
awakenings, and increased the duration of sleep without producing a morning hangover. Subjects
also reported elevated mood and improved daytime functioning the morning after receiving the
dose of melatonin (Suresh, 2017). Sunlight exposure has been documented to effect mood and
exacerbate or alleviate psychiatric symptoms. The most obvious correlation between decreased
sun exposure and declines in mental health is found in Seasonal Affective Disorder.
Additionally, incidences of psychosis increased during times of the year of decreased sunlight
(Gu, 2019). The positive feedback loop between sunlight exposure and melatonin regulation
makes a strong argument for increase sunlight exposure to both manage psychosis and encourage
melatonin production.
Research
Information surround schizophrenia etiology and treatment is consistently growing and
changing and there is limited nursing research focusing on level of melatonin and schizophrenia .
Further nursing research is needed regarding the effect of neonatal sunlight exposure, the role of
the pineal gland and serotonin in melatonin production, variations in melatonin production on
differing skin pigment and genders.
19

Limitations
Several limitations are noted for this integrative review of the literature, including only
studies published in the English language from 1998 To 2021. There tends to be more available
information in the alternative media on the pineal gland and melatonin relative to schizophrenia
symptoms and management.

20

Summary
In summary, this integrative review of the literature focusing on the relationship between
pineal gland abnormalities and melatonin production found no significant correlation between
pineal abnormalities and symptom severity in individuals diagnosed with schizophrenia. Use of
alternative therapies such as melatonin show promise in decreasing symptom severity in those
with a schizophrenia diagnosis. More research is needed into relationship between serotonin and
melatonin, the effectiveness of melatonin in outpatient vs inpatient settings, the effectiveness of
melatonin on various skin pigments, ages, and sexes, and the relationship between physical
pineal abnormalities and their relation to melatonin production.
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Appendices A
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Figure 1: Methodology Consort Chart
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Searched Databases: : ScienceDirect,
Pub MED, Google Scholar, Cumulated
Index to Nursing and Allied Health
Literature (CINAHL), and Elton B.
Stephens Co. (EBESCO)

Included only:
-Dates between 1998-2020
-Research Articles
-Peer Reviewed
-Evidence Based Practice

Used Key terms: "Pineal gland",
"melatonin and schizophrenia", "pineal
gland and schizophrenia", "sleep and
schizophrenia", "melatonin and
treatment for schizophrenia",
"alternative treatments for
schizophrenia", and "pineal volume and
schizophrenia" n= 56

Exclusion:
Studies that did not fit inclusion criteria
or were unattainable n=48

-Topics irrelevant to the pineal gland
and schizophrenia
-Inability to obtain a copy of article

After Further Review of studies n=3

-Existed outside of acceptable
timeframe

Additional studies added from
references n= 1

Total studies to be Reviewed n=4

24

After further review, studies pertaining
to pineal glands relation to
schiozphrenia n= 4

Appendices B
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Table 1: Table of Evidence
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Citation

Study design
and purpose

Sample Relevant Findings
size

Limitations

(Afonso,

present the
findings of wrist
actigraphy and
salivary
melatonin
profiles in a
patient with
schizophrenia
and his
homozygotic
healthy twin.

2

Limitations
1
exist
concerning
collection of
salivary
melatonin.
Since activity
and postural
changes could
affect the
concentration
of circulation
melatonin, in
this study the
subjects were
recommending
staying sitting
during the
sampling
period;
however, our
patient was in
remission, and
his family
supervised the
salivary
collections.
Self-report
questionnaires
like the PSQI

2010)

The affected twin presented
lower melatonin production
and low-threshold dim-light
melatonin onset
(DLMO < 3 pg/mL) as
compared to the non-affected
twin, who presented the normal
nocturnal rise

27

Was a
relationship
found between
pineal gland or
melatonin
abnormalities
and
schizophrenia
development or
symptoms
severity?
1= yes
2=no
3=inconclusive
4= not
applicable/not
tested

Did
compensating
for
abnormalities
improve
symptoms?
1= yes
2=no
3=inconclusive
4=not
applicable

3

(Andrabi,
2019)

to assess the
potential of
melatonin in
attenuating MK801 induced
schizophrenialike behavioral
and brain
neurotoxicity
markers.

6

Our data demonstrated that the
treatment with melatonin
attenuates the schizophrenic
like symptoms in the mice
having a protective effect on
prefrontal cortex region of
brain by mitigating the
alteration of neurotoxicity
markers. The protective effect
of the treatment was shown to
reduced elevation of AChE, cfos expression and
histopathological alterations.
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are limited by
patients' low
insight, and
probably low
expectations
regarding
sleep; other
instruments
could have
produced
larger
differences
between the
twins in this
aspect.
Volumetric
MRI of the
twins' pineal
glands could
have shown
differences in
structure that
might explain
the discrepant
melatonin
levels. Finally,
our results
must be
viewed with
caution due to
comparing
only two
individuals.
Small sample
size

1

1

(MoreraFumero,
2011)

Shamir,
2000

The aim of this
32
research is to
study whether
serum melatonin
level is related
with positive
psychopathology
in a sample of
paranoid
schizophrenia
patients.

The only significant
correlation, with a positive
sign, was the item Conceptual
Disorganisation (P2) with
serum melatonin at 24:00 h
(r = 0.355, p < 0.046).

None stated

3

4

measured
melatonin output
in patients with
chronic
schizophrenia
and assessed the
effects of
melatonin
replacement on
their sleep
quality.

All patients had low melatonin
output. Melatonin replacement
significantly improved restderived sleep efficiency
compared with placebo (83.5%
vs. 78.2%, p = .038) in this
population. Improvement of
sleep efficiency was
significantly greater (p <
.0014) in low-efficiency (80%
vs. 67%) than high-efficiency
sleepers (88% vs. 90%). In
addition, during melatonin
therapy, tendencies toward
shortened sleep latency (by 40
minutes, p < .056) and
increased sleep duration (by 45
minutes, p < .078) were
observed in low- but not highefficiency sleepers.

None stated

4

1
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29

Takahashi,
2019

In this
study, magnetic
resonance
imaging (MRI)
was performed
to measure the
pineal gland
volume in
patients with
schizotypal
disorder and the
results were
compared with
data obtained in
patients with
schizophrenia
and healthy
controls.

246

The present study
None stated
demonstrated similar reduction
of pineal volume in a relatively
large group of patients with
schizotypal disorder
and schizophrenia. We found
no significant relation between
morphologic features of
the pineal gland (such as its
volume and cystic change) and
clinical variables in either
patient group. While we were
unable to directly assess the
mechanism underlying changes
of pineal volume,
low melatonin levels in utero
and/or during early life may
influence neurodevelopment by
inhibiting neuronal
differentiation and axogenesis
(Galván-Arrieta et al., 2017). It
was also reported that the
pineal volume normally
increases during infancy, and
then remains stable (Sumida et
al., 1996). Taken together with
our previous finding of a stable
pineal volume in various stages
of schizophrenia (Takahashi et
al., 2019), it is possible that the
pineal volume indicates a
common vulnerability to
neurodevelopmental pathology
in schizophrenia spectrum
disorders
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3

4

(Onaolapo, The aim of this
study was to
assess the
2017)
potentials of oral
melatonin
supplement in
the management
of induced
schizophrenialike behavioral
and brain
oxidative status
changes, using
an animal
model.
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The results of this study
revealed that melatonin
supplementation was
associated with: 1) a reversal
of ketamine-induced socialinteraction deficits, 2) decrease
in ketamine-induced
hyperlocomotion
(horizontal locomotion and
rearing) and self-grooming
behaviours 3) reversal of
ketamine-induced memorydeterioration 4) reversal of
ketamine-induced changes in
brain antioxidant activity.
Also, at the doses
administered, melatonin’s
overall ability to counteract
ketamine-induced behavioural
changes was better
than haloperidol and
comparable to olanzapine;
while its ability to counteract
brain oxidative stress was a
significant improvement over
olanzapine and haloperidol.
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None stated

4

3

Appendices 3
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Table 2: Teaching Proposal
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Objectives

Timeline

Implementation/Outline Evaluation Plan

Individuals will be able to
identify key factors about
schizophrenia that lead to
decreased quality of life for
the affected individuals.

By the end of the
session

This objective will be
met through a verbal
presentation coupled
with a PowerPoint and
showing of videos
involving firsthand
accounts of what it is
like to live with
schizophrenia.
This objective will be
met though
presentation of statistic
related to health care
exposure in the
schizophrenic
community.
This objective will be
met through enlisting
qualified healthcare
professionals to
demonstrate proper
execution of these
techniques.

Individuals will be able to
By the end of the
identify health disparities
session
faced by those with
schizophrenia and relate these
disparities to systemic causes.

Individuals will be able to
By the end of the
demonstrate an understanding session
of therapeutic communication
and de-escalation as it relates
to individuals experiencing
psychosis.
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Individuals will be able to
verbalize key factors about
schizophrenia that lead to
decreased quality of life for
the affected individuals.

Individuals will be able to
verbalize health disparities
faced by those with
schizophrenia and relate
these disparities to systemic
causes.
Individuals will be able to
demonstrate an understanding
of therapeutic communication
and de-escalation as it relates
to individuals experiencing
psychosis.
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